UA72199C2 - VACCINE CONTAINING AT LEAST ONE PARTICULATE IMMUNOGEN AND ADJUVANTING AMOUNT OF SUBUNITS OF e. COLI HEAT-LABILE ENTEROTOXIN (LTB) FREE FROM CONTAMINATING A SUBUNITS OR TOXIC HOLOTOXIN, ITS USE FOR INDUCTION OF LOCAL AND SYSTEMIC PROTECTIVE RESPONSE AGAINST PARTICULATE IMMUNOGEN UPON MUCOSAL ADMINISTRATION - Google Patents
VACCINE CONTAINING AT LEAST ONE PARTICULATE IMMUNOGEN AND ADJUVANTING AMOUNT OF SUBUNITS OF e. COLI HEAT-LABILE ENTEROTOXIN (LTB) FREE FROM CONTAMINATING A SUBUNITS OR TOXIC HOLOTOXIN, ITS USE FOR INDUCTION OF LOCAL AND SYSTEMIC PROTECTIVE RESPONSE AGAINST PARTICULATE IMMUNOGEN UPON MUCOSAL ADMINISTRATION Download PDFInfo
- Publication number
- UA72199C2 UA72199C2 UA2000063620A UA2000063620A UA72199C2 UA 72199 C2 UA72199 C2 UA 72199C2 UA 2000063620 A UA2000063620 A UA 2000063620A UA 2000063620 A UA2000063620 A UA 2000063620A UA 72199 C2 UA72199 C2 UA 72199C2
- Authority
- UA
- Ukraine
- Prior art keywords
- immunogen
- subunits
- vaccine
- holotoxin
- subunit
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims abstract description 33
- 229960005486 vaccine Drugs 0.000 title claims abstract description 29
- 229930186900 holotoxin Natural products 0.000 title claims abstract description 14
- 230000009885 systemic effect Effects 0.000 title claims abstract description 12
- 101710146739 Enterotoxin Proteins 0.000 title claims abstract description 9
- 239000000147 enterotoxin Substances 0.000 title claims abstract description 9
- 231100000655 enterotoxin Toxicity 0.000 title claims abstract description 9
- 230000004044 response Effects 0.000 title claims abstract description 9
- 231100000331 toxic Toxicity 0.000 title claims description 12
- 230000002588 toxic effect Effects 0.000 title claims description 12
- 230000006698 induction Effects 0.000 title abstract description 3
- 241000588724 Escherichia coli Species 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 14
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 4
- 239000000427 antigen Substances 0.000 claims description 36
- 108091007433 antigens Proteins 0.000 claims description 36
- 102000036639 antigens Human genes 0.000 claims description 36
- 239000002671 adjuvant Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 241000712461 unidentified influenza virus Species 0.000 claims description 18
- 210000004400 mucous membrane Anatomy 0.000 claims description 10
- 230000003053 immunization Effects 0.000 claims description 7
- 238000002649 immunization Methods 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000008105 immune reaction Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims 5
- 244000068988 Glycine max Species 0.000 claims 2
- 241000894006 Bacteria Species 0.000 abstract description 8
- 244000052769 pathogen Species 0.000 abstract description 6
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract description 2
- 241000537222 Betabaculovirus Species 0.000 abstract 1
- 101710154606 Hemagglutinin Proteins 0.000 description 26
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 26
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 26
- 101710176177 Protein A56 Proteins 0.000 description 26
- 239000000185 hemagglutinin Substances 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 18
- 241000700605 Viruses Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 7
- 229940031626 subunit vaccine Drugs 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000001571 immunoadjuvant effect Effects 0.000 description 4
- 229960003971 influenza vaccine Drugs 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940126577 synthetic vaccine Drugs 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000006391 Luria-Bertani Medium Substances 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97203671A EP0919243A1 (en) | 1997-11-25 | 1997-11-25 | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| PCT/EP1998/007553 WO1999026654A1 (en) | 1997-11-25 | 1998-11-24 | Vaccines with an ltb adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72199C2 true UA72199C2 (en) | 2005-02-15 |
Family
ID=8228966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000063620A UA72199C2 (en) | 1997-11-25 | 1998-11-24 | VACCINE CONTAINING AT LEAST ONE PARTICULATE IMMUNOGEN AND ADJUVANTING AMOUNT OF SUBUNITS OF e. COLI HEAT-LABILE ENTEROTOXIN (LTB) FREE FROM CONTAMINATING A SUBUNITS OR TOXIC HOLOTOXIN, ITS USE FOR INDUCTION OF LOCAL AND SYSTEMIC PROTECTIVE RESPONSE AGAINST PARTICULATE IMMUNOGEN UPON MUCOSAL ADMINISTRATION |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6793928B1 (enExample) |
| EP (2) | EP0919243A1 (enExample) |
| JP (1) | JP4235359B2 (enExample) |
| KR (1) | KR100575019B1 (enExample) |
| CN (1) | CN1227032C (enExample) |
| AT (1) | ATE238809T1 (enExample) |
| AU (1) | AU747061C (enExample) |
| BR (1) | BR9815413A (enExample) |
| CA (1) | CA2311492C (enExample) |
| CZ (1) | CZ299770B6 (enExample) |
| DE (1) | DE69814177T2 (enExample) |
| DK (1) | DK1071456T3 (enExample) |
| ES (1) | ES2198089T3 (enExample) |
| HU (1) | HU226214B1 (enExample) |
| IL (2) | IL135905A0 (enExample) |
| NO (1) | NO324690B1 (enExample) |
| NZ (1) | NZ504396A (enExample) |
| PL (1) | PL190925B1 (enExample) |
| PT (1) | PT1071456E (enExample) |
| RU (1) | RU2211050C2 (enExample) |
| SK (1) | SK284572B6 (enExample) |
| TR (1) | TR200001485T2 (enExample) |
| UA (1) | UA72199C2 (enExample) |
| WO (1) | WO1999026654A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| KR20010043441A (ko) | 1998-05-08 | 2001-05-25 | 더 유니버시티 오브 브리스톨 | 백신용 면역조절제 |
| AU2003261492B2 (en) * | 1998-05-08 | 2006-09-07 | Trident Pharmaceuticals, Inc. | Vaccine |
| EP1075274A2 (en) * | 1998-05-08 | 2001-02-14 | University Of Bristol | Immunomodulators for vaccines |
| EP1221970B1 (en) * | 1999-10-18 | 2014-02-19 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for stimulating an immune response against infectious agents |
| RU2223783C1 (ru) * | 2002-07-05 | 2004-02-20 | Российская медицинская академия последипломного образования | Способ профилактики гриппа и острых респираторных заболеваний у часто болеющих детей |
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| EP1708744A4 (en) * | 2003-12-09 | 2009-07-15 | Intercell Usa Inc | GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees |
| EP1930025B1 (en) | 2005-08-05 | 2013-05-01 | The University of Tokushima | ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE |
| TWI397419B (zh) * | 2006-03-22 | 2013-06-01 | Abbott Biologicals Bv | 病毒顆粒的鼻內或吸入給藥 |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| CN101522706B (zh) | 2006-10-12 | 2013-09-04 | P.安杰莱蒂分子生物学研究所 | 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途 |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| AU2008343745B2 (en) | 2007-10-01 | 2012-05-10 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CN104379170B (zh) * | 2012-06-20 | 2017-05-03 | 国立大学法人东京大学 | 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物 |
| CN106170551B (zh) | 2013-12-16 | 2020-01-07 | 财团法人农业科技研究院 | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 |
| EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
| CN111344397A (zh) * | 2017-11-01 | 2020-06-26 | 默沙东公司 | 巨细胞病毒的稳定制剂 |
| AU2019207600B2 (en) | 2018-01-09 | 2025-01-09 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| EP3768302B1 (en) | 2018-03-20 | 2025-05-07 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| EP4275761A3 (en) | 2018-03-20 | 2024-02-28 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| WO2020227263A1 (en) | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Alkaline phosphate-based oncology treatments |
| EP3975999A4 (en) | 2019-06-03 | 2023-07-19 | Theriva Biologics, Inc. | ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| CN113616783B (zh) * | 2020-05-08 | 2025-08-08 | 昱厚生技股份有限公司 | 使用免疫调节剂和包含所述免疫调节剂的疫苗组合物预防或治疗冠状病毒感染的方法 |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| TWI896302B (zh) * | 2024-08-22 | 2025-09-01 | 國立清華大學 | 重組蛋白及其製備方法、包含重組蛋白的疫苗蛋白質佐劑及重組蛋白用於預防呼吸道疾病的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH589453A5 (enExample) | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| AU4754490A (en) * | 1988-12-07 | 1990-06-26 | University Of Leicester | Heat-labile toxin b subunit fusion proteins |
| US5241053A (en) * | 1990-09-05 | 1993-08-31 | Takeda Chemical Industries, Ltd. | Fused proteins comprising glycoprotein gD of HSV-1 and LTB |
| GB9513733D0 (en) * | 1995-07-05 | 1995-09-06 | Univ Bristol | Therapeutic agents |
-
1997
- 1997-11-25 EP EP97203671A patent/EP0919243A1/en not_active Withdrawn
-
1998
- 1998-11-24 RU RU2000116260/14A patent/RU2211050C2/ru not_active IP Right Cessation
- 1998-11-24 US US09/555,139 patent/US6793928B1/en not_active Expired - Fee Related
- 1998-11-24 BR BR9815413-3A patent/BR9815413A/pt not_active IP Right Cessation
- 1998-11-24 CN CNB988115492A patent/CN1227032C/zh not_active Expired - Fee Related
- 1998-11-24 AU AU18750/99A patent/AU747061C/en not_active Ceased
- 1998-11-24 SK SK776-2000A patent/SK284572B6/sk not_active IP Right Cessation
- 1998-11-24 CZ CZ20001895A patent/CZ299770B6/cs not_active IP Right Cessation
- 1998-11-24 WO PCT/EP1998/007553 patent/WO1999026654A1/en not_active Ceased
- 1998-11-24 NZ NZ504396A patent/NZ504396A/en not_active IP Right Cessation
- 1998-11-24 IL IL13590598A patent/IL135905A0/xx active IP Right Grant
- 1998-11-24 EP EP98963503A patent/EP1071456B1/en not_active Expired - Lifetime
- 1998-11-24 ES ES98963503T patent/ES2198089T3/es not_active Expired - Lifetime
- 1998-11-24 JP JP2000521855A patent/JP4235359B2/ja not_active Expired - Fee Related
- 1998-11-24 CA CA2311492A patent/CA2311492C/en not_active Expired - Fee Related
- 1998-11-24 UA UA2000063620A patent/UA72199C2/uk unknown
- 1998-11-24 TR TR2000/01485T patent/TR200001485T2/xx unknown
- 1998-11-24 PT PT98963503T patent/PT1071456E/pt unknown
- 1998-11-24 PL PL340635A patent/PL190925B1/pl unknown
- 1998-11-24 DE DE69814177T patent/DE69814177T2/de not_active Expired - Lifetime
- 1998-11-24 HU HU0100058A patent/HU226214B1/hu not_active IP Right Cessation
- 1998-11-24 KR KR1020007005665A patent/KR100575019B1/ko not_active Expired - Fee Related
- 1998-11-24 AT AT98963503T patent/ATE238809T1/de active
- 1998-11-24 DK DK98963503T patent/DK1071456T3/da active
-
2000
- 2000-05-01 IL IL135905A patent/IL135905A/en not_active IP Right Cessation
- 2000-05-22 NO NO20002613A patent/NO324690B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2211050C2 (ru) | Вакцины с адъювантом ltb | |
| Sui et al. | Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant | |
| US8182821B2 (en) | Flu vaccine admixture of mannan and flu antigen | |
| WO2023023940A1 (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| CN103596588A (zh) | 用于犬呼吸道疾病综合征的组合物 | |
| WO2021252450A1 (en) | Phage display vaccine for covid-19 using a novel peptide sequence | |
| CN109880839A (zh) | 猪支原体肺炎和猪圆环病毒二联基因工程疫苗制备方法 | |
| AU778957B2 (en) | Bacterial membrane fractions with adjuvant effect | |
| WO2008037033A1 (en) | Flu vaccine admixture of mannan and flu antigen | |
| US11931410B1 (en) | SARS-CoV-2 mRNA vaccine and preparation method and use thereof | |
| RU2850189C2 (ru) | Рекомбинантный гибридный белок, полученный из HR-области белка S2 SARS-CoV-2, и применение рекомбинантного гибридного белка | |
| RU2850189C9 (ru) | Рекомбинантный гибридный белок, полученный из HR-области белка S2 SARS-CoV-2, и применение рекомбинантного гибридного белка | |
| HK1031102B (en) | Vaccines with an ltb adjuvant | |
| MXPA00005127A (en) | Vaccines with an ltb adjuvant | |
| WO1994022917A1 (en) | Cross-reactive influenza a immunization | |
| HK1190638B (en) | Compositions for canine respiratory disease complex |